U.S., Dec. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07261644) titled 'Phase III Study of 608 in the Treatment of Active Ankylosing Spondylitis in Adults' on Nov. 21.
Brief Summary: This study will evaluate the efficacy and safety of 608 in patients with AS.
Study Start Date: Nov. 07
Study Type: INTERVENTIONAL
Condition:
Ankylosing Spondylitis
Intervention:
DRUG: 608 dose
608 subcutaneous (SC) injection.
DRUG: Placebo
Placebo subcutaneous (SC) injection.
Recruitment Status: RECRUITING
Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....